000538 云南白药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入30,654,2142.47%40,033,30139,111,29236,488,37336,373,919
减:营业总成本26,074,7612.33%35,206,79735,082,75032,087,16831,739,818
    其中:营业成本21,439,5900.10%28,864,76628,744,51826,883,48526,498,435
               财务费用(39,030)-69.60%(155,555)(259,244)(342,878)(258,281)
               资产减值损失(66,217)372.71%(91,231)(58,128)(664,339)(143,220)
公允价值变动收益81,760-535.49%136,837123,566(619,903)(1,929,217)
投资收益951,17138.83%776,937779,011868,1981,044,401
    其中:对联营企业和合营企业的投资收益894,37827.60%774,280628,532732,233(21,100)
营业利润5,605,05311.86%5,711,6224,830,5063,371,2793,485,169
利润总额5,615,09912.01%5,684,7204,818,0123,377,0023,481,646
减:所得税费用825,92820.83%917,647695,451536,593683,986
净利润4,789,17010.61%4,767,0724,122,5612,840,4102,797,661
减:非控股权益12,050305.41%17,65728,779(160,716)(7,256)
股东净利润4,777,12010.41%4,749,4154,093,7823,001,1262,804,917

市场价值指针
每股收益 (元) *2.68010.74%2.6602.2901.9002.210
每股派息 (元) *1.019--2.3982.0771.5201.600
每股净资产 (元) *22.269-1.95%21.76422.19421.42829.800
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容